L-Ornithine for Insomnia

L-ornithine for insomnia rests on a single Japanese randomized controlled trial in adults reporting stress-related fatigue, where 400 mg daily for eight weeks improved subjective sleep quality and lowered the cortisol-to-DHEA ratio. It is a low-risk, low-cost thing to test, but it has not been replicated and there is no objective sleep-architecture data.

Ornithine accelerates urea-cycle clearance of ammonia, and the trial authors proposed that lower ammonia load plus a shifted cortisol-to-DHEA ratio reduces physiological stress signalling that interferes with sleep onset and depth. This is a plausible mechanism rather than a demonstrated one; no study has shown ornithine acting directly on sleep-regulating neurotransmission.

The core evidence is Miyake et al., a randomized, double-blind, placebo-controlled trial of 52 adults with self-reported fatigue who took 400 mg/day of L-ornithine or placebo for eight weeks. The ornithine group reported improved sleep quality on the OSA-MA questionnaire and showed a reduced serum cortisol-to-DHEA-S ratio. Related work has shown ornithine lowers blood ammonia after exercise, supporting the mechanistic premise. What is missing is any independent replication, any polysomnography, and any trial in people with diagnosed insomnia rather than general fatigue. The honest reading is one positive small trial in a non-clinical population — enough to justify an eight-week personal trial, not enough to recommend it over sleep hygiene, CBT-I, or better-evidenced options.

People whose insomnia is driven by pain, apnoea, restless legs, or an established anxiety disorder are unlikely to respond, since none of those involve the pathway ornithine touches.